Puma Biotechnology, Inc. (PBYI): Cost of Revenue
$58.16M
Year ended 2025-12-31
$58.20M
Trailing 12 months to 2026-06-30
+1.8%
3-year compound annual growth
+8.1%
5-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $58.16M | -9.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $64.40M | +2.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $62.68M | +13.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $55.09M | -13.5% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $63.70M | +61.8% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $39.37M | +7.0% | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | $36.81M | +6.3% | 2022-03-03, From 2019-01-01 |
| 2018-12-31 | $34.62M | +521.3% | 2019-03-01, From 2018-01-01 |
| 2017-12-31 | $5.57M | n/a | 2019-03-01, From 2017-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $58.16M | -9.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $39.46M | -37.5% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $113.25M | +50.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $67.93M | +38.0% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $19.49M | +45.8% |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $151.75M | +0.6% |
| Lifevantage Corp (LFVN) | 2026-06-30 | $40.97M | -8.7% |
| Cryoport, Inc. (CYRX) | 2025-12-31 | $93.12M | +6.9% |
| Evolus, Inc. (EOLS) | 2025-12-31 | $100.07M | +19.2% |
Compare PBYI, AKBA, SDGR, HROW side by side · Screen every company in Pharmaceutical Preparations ↗